To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
Authors:
- Han Yi LeeHLHan Yi Lee
- Whee Sze OngWOWhee Sze Ong
- Vivianne Tjan-HeijnenVTVivianne Tjan-Heijnen
- Matteo LambertiniMatteo Lambertini
- Yen Shen LuYLYen Shen Lu
- Kyong Hwa ParkKPKyong Hwa Park
- Yasuaki SagaraYSYasuaki Sagara
- Maria VidalMVMaria Vidal
- Ander UrruticoecheaAUAnder Urruticoechea
- Mafalda OliveiraMafalda Oliveira
- Eva CiruelosECEva Ciruelos
- Nicholas ZdenkowskiNZNicholas Zdenkowski
Open Access
- 12 October 2026
- journal article
- Published by Elsevier in The Breast
- Vol. 90
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecanBreast Cancer, 2026
- Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE studyThe Breast, 2025
- Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patientsEuropean Journal of Cancer, 2025
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)The Breast, 2024
- Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United StatesValue in Health, 2023
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelDrug Safety, 2023
- Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortESMO Open, 2021
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studyThe Lancet Oncology, 2020
- Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysisBreast Cancer Research and Treatment, 2017
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013